Understanding Regulatory Considerations During Feasibility Assessments

Feasibility assessments are a critical step in clinical trial start-up, allowing sponsors and CROs to evaluate whether potential sites can successfully execute a protocol. However, beyond site infrastructure, patient pools, and investigator experience, regulatory compliance is equally vital. Inadequate attention to regulatory requirements during feasibility can lead to delays, rejections, or audit findings. This guide outlines the essential regulatory elements that must be reviewed as part of every feasibility evaluation.

The Role of Regulatory Compliance in Feasibility

Clinical trial regulations set the foundation for ethical conduct, subject protection, and data integrity. Regulatory oversight agencies—such as the USFDA, EMA, and CDSCO—require documented evidence that investigational sites are capable of meeting regulatory standards before approval.

During feasibility, sponsors must verify that a site is not only suitable for operations but also aligns with regional and international guidelines like ICH-GCP. Regulatory gaps at this stage can lead to costly start-up delays or compliance issues post-initiation.

Key Regulatory Checks During Feasibility Assessments

1. Licensing and Accreditation of Site and Investigators

• Principal Investigator (PI) must have valid medical licensure for the country of operation
• Site should be registered with national regulatory authorities (where applicable)
• Verify any historical suspensions, sanctions, or non-compliance records

2. IRB/EC Review Capabilities

• Confirm whether the site has access to a functioning Institutional Review Board or Ethics Committee
• Assess average timelines for initial and continuing review
• Check if the EC complies with national GCP regulations and maintains adequate documentation

3. Informed Consent Process Oversight

• Ensure that informed consent SOPs align with Pharma SOP documentation
• Review the site’s history with vulnerable populations, if applicable
• Determine if translations and local adaptations are supported by EC

4. Regulatory Submissions and Approvals

• Check site familiarity with regulatory submission procedures for CTAs or INDs
• Review documentation timelines from past trials (e.g., CDSCO SUGAM Portal, EMA Clinical Trial Portal)
• Ensure readiness to handle amendments, notifications, and queries during the trial

5. GCP Training and Documentation

• Confirm that all site staff have completed recent GCP training (within 2 years)
• Request training certificates or rosters for documentation
• Evaluate understanding of ICH E6 (R2) and relevant national adaptations

Country-Specific Regulatory Expectations

Each region imposes specific requirements during feasibility. For example:

• India (CDSCO): Sites must be registered with the CDSCO and ECs accredited under NABH or equivalent bodies
• USA (FDA): Requires Form 1572 and Investigator CVs submitted to the IND file
• EU (EMA): Site details must be entered in the CTIS for each trial
• UK (MHRA): Requires pre-approval of site and PI in trial notification

Understanding these differences ensures proper selection and preparedness of sites globally.

Documentation for the Trial Master File (TMF)

As per ICH-GCP and StabilityStudies.in recommendations, feasibility documentation with regulatory components must be maintained in the TMF, including:

• Signed feasibility questionnaires with regulatory declarations
• Copies of licenses, CVs, and GCP training certificates
• EC registration documents
• Feasibility decision-making justifications

Creating a Regulatory Feasibility Checklist

Sponsors should include a dedicated regulatory section in their feasibility checklist covering:

• PI licensing status and experience
• EC operational capability and accreditation
• Historical compliance data (e.g., audit findings, inspection outcomes)
• Submission readiness and GCP compliance

This can be developed into a site scorecard and integrated with the overall site qualification process.

Common Pitfalls and How to Avoid Them

• Assuming EC availability: Always confirm the EC is currently functioning and accepting reviews
• Overlooking licensing renewals: PI or staff may have expired registrations
• Inconsistent GCP records: Ensure centralized verification of training validity
• Lack of audit documentation: Request recent inspection reports, especially if conducted by agencies like TGA or ANVISA

Integrating with Site Feasibility SOPs

Your feasibility SOP should clearly assign responsibilities to regulatory affairs or clinical operations teams for verifying these elements. Regulatory feasibility should be completed before final site approval and revisited during site initiation.

Conclusion

Regulatory considerations are a foundational component of feasibility assessments. They ensure that sites are compliant, inspection-ready, and capable of meeting trial expectations. By embedding regulatory checks early in the feasibility process, sponsors can avoid costly delays and ensure seamless clinical trial execution with full compliance to global standards.

How ICH Drives Global Harmonization of GCP Standards in Clinical Research

In the complex ecosystem of global clinical research, consistent and ethical conduct of trials across borders is a non-negotiable necessity. The International Council for Harmonisation (ICH) plays a central role in ensuring this consistency through its Good Clinical Practice (GCP) guidelines. With ICH E6 as the cornerstone, the ICH initiative has enabled a cohesive framework that is respected and implemented by regulatory bodies worldwide, from USFDA to CDSCO.

This article explores how ICH promotes GCP harmonization across regions, the practical implications for stakeholders, and how it influences the integrity and efficiency of global clinical trials.

Understanding the ICH Framework:

The ICH was established in 1990 as a tripartite initiative between the EU, US, and Japan. It has since expanded to include regulatory bodies and pharmaceutical industry stakeholders from around the world. The core mission is to achieve greater regulatory harmonization to ensure safe, effective, and high-quality medicines.

One of its most impactful outputs is the ICH E6 Good Clinical Practice guideline, which provides a unified standard for the design, conduct, monitoring, recording, and reporting of clinical trials. This ensures data credibility and the protection of human subjects across jurisdictions.

Why Harmonization of GCP Matters

• Reduces duplication of clinical studies across countries
• Accelerates the global development and approval of drugs
• Promotes ethical treatment of participants regardless of location
• Improves data consistency and audit readiness across sites
• Enables mutual recognition and reliance on regulatory inspections

In essence, harmonization improves efficiency and reduces risk for sponsors while fostering a level playing field for all trial participants.

Core ICH GCP Guidelines Driving Harmonization:

1. ICH E6(R2) GCP: Widely adopted globally, this provides the foundation for unified clinical trial conduct.
2. ICH E8(R1): Focuses on general principles and clinical development quality, further supporting GCP implementation.
3. ICH E9(R1): Introduces the estimand framework, improving how treatment effects are measured across regions.
4. ICH E17: Offers guidelines for multiregional clinical trials (MRCTs), directly addressing cross-regional variability.

Adoption of ICH GCP by Global Regulatory Agencies:

The ICH guidelines are no longer confined to founding members. Today, numerous countries and regions have adopted or adapted ICH GCP to their local regulations:

• EMA: Fully aligned with ICH GCP across EU member states.
• CDSCO (India): Incorporated ICH E6 into its GCP Guidelines (2016), ensuring harmonized trials across India.
• PMDA (Japan): Actively participates in ICH working groups and incorporates updates swiftly.
• Health Canada: Applies ICH GCP as a reference standard for all trials conducted in Canada.
• SAHPRA (South Africa): Recognizes ICH E6(R2) for trial conduct and inspections.
• TGA (Australia): Accepts ICH-compliant data for regulatory submissions and audits.

How ICH Facilitates Harmonized Implementation:

1. Training and Educational Initiatives

ICH conducts global workshops and supports training resources to build awareness and capability for implementing GCP. These materials align stakeholders with best practices, including GMP guidelines where relevant.

2. Step-by-Step Guideline Revisions

ICH develops and revises guidelines in a consensus-driven, transparent process. Updates such as E6(R3) are discussed globally and rolled out in stages to ensure consistency in adoption and allow adequate training lead time.

3. Promoting Regulatory Reliance

With harmonized GCP standards, regulatory authorities can rely on inspections and reviews conducted by peers in other regions, saving time and reducing the burden of duplicative efforts. This facilitates efficient approval of multiregional trials.

Real-World Impact: Case of Multiregional Trials

Multiregional Clinical Trials (MRCTs) are a clear beneficiary of ICH GCP harmonization. Sponsors can conduct a single global trial instead of separate national trials, reducing costs and speeding up patient access. As per EMA guidance, data from MRCTs designed per ICH E17 and E6 standards are fully acceptable for regulatory submissions within the EU.

Similarly, when running trials involving Stability Studies or bioequivalence studies across sites in Asia, Europe, and North America, ICH alignment ensures consistency in documentation, monitoring, and data interpretation.

Common Challenges in GCP Harmonization

• Local ethics committee practices may still vary despite global guidelines
• Diverse expectations for document translations and site qualifications
• Variability in electronic system acceptance (e.g., eSource data)
• Differences in enforcement and inspection rigor across regions

However, these challenges are gradually diminishing as regulators align further through ICH updates and mutual recognition initiatives.

Best Practices for GCP Compliance in a Harmonized Environment:

1. Design studies following ICH E6 and E8 quality principles from the outset.
2. Ensure all SOPs align with Pharma SOP guidelines and local regulatory adaptations.
3. Train global teams in both ICH GCP and country-specific requirements.
4. Use centralized systems with audit trails and risk-based monitoring.
5. Engage with regional regulatory consultants for submission readiness.

Conclusion

The ICH initiative remains one of the most powerful forces for regulatory convergence in the clinical trial world. Its work in establishing and updating GCP standards has enabled sponsors, CROs, and regulators to work from a shared playbook—ultimately leading to safer, faster, and more efficient trials. As global collaboration in drug development increases, ICH will continue to drive harmonization, ensuring clinical trials meet the same high standards regardless of where they are conducted.